论文部分内容阅读
大肠埃希菌是临床常见致病菌或机会致病菌.也是院内获得性感染的重要病原菌。其耐药性的变迁和多重耐药的出现,主要与耐药基因编码酶有关,其中以质粒介导的超广谱β-内酰胺酶(ESBLs)和AmpC酶最为重要。ES- BLs和质粒型AmpC酶自发现以来,迅速在世界范围内不同菌种中流行,以大肠埃希菌和肺炎克雷伯菌为甚。其检出率逐渐升高,新型酶不断被发现,已发现的ESBLs基因型>200种、AmpC酶基因型>30种。我们在最近一项关于大肠埃希菌β-内酰胺类抗生素耐药相关基因的研究中,发现1株严重多重耐药的大肠埃希菌(ZY163)同时携带2种新型ESBLs和AmpC酶,现报告如下:
Escherichia coli is a common clinical pathogenic bacteria or opportunistic pathogens, but also an important pathogen acquired nosocomial infection. The changes of drug resistance and the emergence of multi-drug resistance are mainly related to the enzyme-resistance genes encoding enzymes, of which plasmid-mediated ESBLs and AmpC enzymes are the most important. Since discovery, ES-BLs and plasmid-type AmpC enzymes have rapidly become popular among different strains worldwide, with Escherichia coli and Klebsiella pneumoniae. The detection rate was gradually increased, a new type of enzyme was found, ESBLs genotypes have been found> 200 species, AmpC enzyme genotype> 30 species. In a recent study on the genes responsible for the resistance to β-lactam antibiotics in Escherichia coli, we found that two strains of novel multi-drug resistant Escherichia coli (ZY163) carrying two novel ESBLs and AmpC enzymes The report is as follows: